The treatment of hypophosphatemic rickets is done by the oral administration of phosphorus and vitamin D. Currently, growth hormone [15] and KRN23 [16] a recombinant human monoclonal antibody targeting FGF23 are under investigation for hypophosphatemic rickets. This evidence concerns the gene GH1 and hypophosphatemic rickets.